Advances in Stereotactic and Functional Neurosurgery 10 1993
DOI: 10.1007/978-3-7091-9297-9_18
|View full text |Cite
|
Sign up to set email alerts
|

Brachytherapy—Interstitial Implant Radiosurgery

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
8
0

Year Published

1994
1994
2012
2012

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 15 publications
(8 citation statements)
references
References 14 publications
0
8
0
Order By: Relevance
“…Characteristic tissue effects associated with the high dose zone in the vicinity of the implanted source (≥ 200Gy) have been described experimentally, i. e. the development of circumscribed radionecrosis with temporary changes in capillary permeability with a sometimes extensive oedema and concomitantly reduced regional cerebral blood flow [18-20,55,56] (see below).…”
Section: Reviewmentioning
confidence: 99%
“…Characteristic tissue effects associated with the high dose zone in the vicinity of the implanted source (≥ 200Gy) have been described experimentally, i. e. the development of circumscribed radionecrosis with temporary changes in capillary permeability with a sometimes extensive oedema and concomitantly reduced regional cerebral blood flow [18-20,55,56] (see below).…”
Section: Reviewmentioning
confidence: 99%
“…This is a clear advantage over open microsurgery, which carries a serious risk of permanent neurologic and endocrine sequelae. 6 This increases the therapeutic ratio and allows for repeated seed implantations if the initial effect is incomplete. The principle of interstitial radiosurgery may be advantageous in avoiding potential radiation-induced side effects as the application of gamma radiation from the center of the lesion can be performed with minimal exposition of extralesional brain tissue to gamma radiation (see figure 1).…”
Section: Resultsmentioning
confidence: 99%
“…Considerable data exist for brachytherapeutic treatment of low-grade gliomas (WHO I pilocytic astrocytomas, WHO II astrocytomas, oligoastrocystomas and oligodendrogliomas), both in children and adults (Julow et al, 2007;Korinthenberg et al, 2010;Kreth et al, 1995;Mehrkens et al, 2004;Mundinger et al, 1991;Ostertag et al, 1993;Ruge et al, 2011a;Schatz et al, 1994;Suchorska et al, 2011).…”
Section: Sbt For Low-grade Gliomas (Who I and Ii)mentioning
confidence: 99%